Video: How are Cell Therapy Trials Really Faring?
Discover how cell therapy trials are really faring, from patient recruitment and funding challenges to advances in allogeneic and in vivo CAR therapies.
00:02: This is a complex question with many different factors. So, based on data from the first half of the year, 15% of terminated trials stated problems with patient accrual as their reasons for trial termination. And this really highlights how important it is for patients to be able to…
00:20: …access these therapies at sites that are near to them. A further 9% of terminated trials stated funding as a reason for termination. With patients required to be inpatient at facilities for up to a month in order to ensure there are no side effects or toxicities, it’s important that sites…
00:38: …are able to provide this care. So far, allogeneic therapies have not been able to replicate the success with allogeneic therapies, but this looks like it may be about to change.
00:48: With Caribou Biosciences presenting a 51% progression-free survival at 12 months recently in a press release. With the recent emergence of in vivo CAR therapies, there are now 36 in vivo CAR trials. And with the first clinical data starting to emerge, it’s never been more…
01:06: …important to benchmark and correlate data before translation to success. Myeloid Therapeutics recently presented data at SITC for their in vivo CAR-M Trop-2 targeting, and this showed a partial response in hormone receptor-positive breast cancer.
01:24: Additionally, Personalis BioTherapeutics recently announced that they dosed their first patient with a in vivo CAR-T >> CD19 targeting therapy. Another important factor when designing trials is preconditioning regimen. With some companies like Cartesian Therapeutics even looking to remove…
01:39: …preconditioning regimen step entirely. With 680 cell therapy trials initiated or due to be initiated this year, Beike Biotechnology can give you confidence and inspire success in all of your therapies.
01:52: Reach out to us if you want to know more.
Learn More About Cell Therapy
- The Most Comprehensive Way to Search the Cell Therapy Development Landscape: Unique search ontologies based on Cell Therapy drug and trial characteristics
- Market Leading Approach to Cell Therapy Preclinical & Clinical Data Curation: Manual curation of key Cell Therapy research and development data points by Cell Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cell Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
